Andrographolide

Category	Influenza Virus
CAS	5508-58-7
Description	Andrographolide is a labdane diterpenoid that is the main bioactive component of the medicinal plant Andrographis paniculata. It has the effects of dispelling heat, detoxification, anti-inflammatory and relieving pain.

Quotation Now

Product Information

Synonyms	(3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methyle ne-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxy-2-oxolanone
Molecular Weight	350.45
Molecular Formula	C20H30O5
Canonical SMILES	CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)CO)O
InChI	InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1
InChIKey	BOJKULTULYSRAS-OTESTREVSA-N
Boiling Point	557.3±50.0 °C at 760 mmHg
Melting Point	229-232°C
Flash Point	195.5±23.6 °C
Purity	>98%
Density	1.21g/cm3
Solubility	In Vitro: DMSO : 100 mg/mL(285.35 mM;Need ultrasonic) H2O : < 0.1 mg/mL(insoluble) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution
Appearance	Powder
Application	anticancer
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Animal Admin	Mice are injected i.p. with Andrographolide (5 or 30 mg/kg body weight) or PBS as a control 1 day before injection of LPS (5 μg/g body weight). The left femurs of all animals are scanned with a high-resolution micro-CT at a resolution of 9 μm.
Complexity	597
Exact Mass	350.209320
Index Of Refraction	1.568
In Vitro	Andrographolide (AP) concentration-dependently suppresses receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclast differentiation and bone resorption in vitro and reduces the expression of osteoclast-specific markers. Andrographolide also inhibits the ERK/MAPK signalling pathway without affecting p38 or JNK signalling. Andrographolide inhibits osteoclast differentiation of RAW 264.7 cells in a concentration-dependent manner. Andrographolide suppresses osteoclast formation in a concentration-dependent manner without any obvious cytotoxic effects, in both BMMs and RAW 264.7 cells.
In Vivo	Treatment with Andrographolide (5 or 30 mg/kg) reduces the extent of bone loss induced by LPS. Moreover, Andrographolide slightly increases the BMD and cortex thickness compared to LPS treatment.
PSA	86.99000
Target	NF-κB; SARS-CoV; Influenza Virus; Autophagy
Vapor Pressure	0.0±3.4 mmHg at 25°C
XLogP3-AA	2.2